Abstract Library

#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial

Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Santos M, Lanillos J, Lopez C, Alonso Gordoa T, Benavent M,

Keywords: pancreatic, neuroendocrine, mutations, correlation,

#2051 Do We Need Hormonal Therapy for Pancreatic Neuroendocrine Tumors? An Effort to Reduce the Size of PanNETs

Introduction: Pancreatic neuroendocrine tumors although rare , have been significantly increased over the past few decades. They range from indolent to highly aggressive in nature. Just like breast and endometrial carcinoma are hormonal dependant,

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: high positive ERβ, Hormonal therapy, small size PanNET,

#1549 Ectopic Cushing Syndrome in a Patient with Metastatic Medullary Thyroid Carcinoma

Introduction: Ectopic Cushing syndrome was reported in 0.6% of patients with medullary thyroid carcinoma; it usually occurred in metastatic cases and significantly increases mortality.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Poiana C

Authors: Trifanescu R, Caragheorgheopol A, Schipor S, Dumitrascu A, Baciu I,

Keywords: Ectopic Cushing syndrome, medullary thyroid carcinoma,

#1032 Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors

Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Walter T

Authors: Benslama N, Bollard J, Vercherat C, Roche C, Hervieu V,

Keywords: neuroendocrine tumors, everolimus, markers, p-p70S6K,

#495 Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): Updated Results From a Single-Center Case Control Study

Introduction: PNETs are uncommon and little is known about risk factors and association with other cancers.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Halfdanarson T, Bamlet W, McWilliams R, Hobday T, Burch P,

Keywords: pancreatic neuroendocrine tumors, risk factors,